Trials / Terminated
TerminatedNCT02107378
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- SOTIO a.s. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
Detailed description
The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care chemotherapy may result in prolongation of Overall Survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DCVAC/OvCa | DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin |
| DRUG | Standard of Care (Paclitaxel or topotecan or doxorubicin) | Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-04-08
- Last updated
- 2016-11-30
Locations
12 sites across 3 countries: Czechia, Germany, Poland
Source: ClinicalTrials.gov record NCT02107378. Inclusion in this directory is not an endorsement.